ArticleJournal of the Endocrine Society2026
Interpretable Machine Learning Model for Survival Prediction in Pediatric Adrenocortical Tumors.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpretable Machine Learning Model for Survival Prediction in Pediatric Adrenocortical Tumors.Journal of the Endocrine Society · 2026Article
- Artificial Intelligence and Machine Learning in Pediatric Endocrine Tumors: Opportunities, Pitfalls, and a Roadmap for Trustworthy Clinical Translation.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Pediatric adrenocortical tumors (pACTs) are rare and clinically heterogeneous. Existing risk stratification systems rely on fixed thresholds and linear assumptions, which may limit their prognostic accuracy-particularly for nonmetastatic, locally advanced cases. We aimed to develop an interpretable machine learning (ML) model for individualized survival prediction using only routine clinical features. Methods: We retrospectively analyzed 97 patients with pACT from the German Pediatric Oncology Hematology-Malignant Endocrine Tumors Registry (1997-2024). An Extreme Gradient Boosting Cox proportional hazards model was trained using 4 features-tumor volume, distant metastases, pathologic T stage, and resection status-identified via systematic feature evaluation across 11 737 model combinations. Performance was assessed using a stratified 80/20 train-test split, 500 bootstrap iterations, and Harrell's concordance index (C-index). SHapley Additive exPlanations (SHAP) were used for interpretability. Results: The model achieved strong prognostic performance (test-set C-index: 0.925; bootstrap mean: 0.891, 95% confidence interval: 0.817-0.946). SHAP analysis confirmed the dominant influence of metastatic status, followed by tumor volume, T stage, and resection status. The model uncovered nonlinear and additive effects, including a SHAP- and bootstrap-guided tumor volume cut-off (190 mL, 95% confidence interval 127-910 mL) that only slightly differed from conventional thresholds. Stratification remained robust in subgroups, including nonmetastatic patients with advanced local disease. Conclusion: This interpretable ML model enables individualized survival prediction in pACT using only routine clinical data. It offers a clinically accessible and clinically meaningful complement to existing scoring systems, particularly in patients with ambiguous risk profiles who may benefit from more personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.